404 related articles for article (PubMed ID: 15060539)
1. IP litigation in China could drive innovation.
Jia H
Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
[No Abstract] [Full Text] [Related]
2. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
3. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
4. Enforcing pharmaceutical and biotech patent rights in China.
Zhang YP; Deng MM
Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
[No Abstract] [Full Text] [Related]
5. The interaction between intellectual property and drug regulatory systems: global perspectives.
Madden EA
IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
[TBL] [Abstract][Full Text] [Related]
6. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
7. Intellectual property. Fixing the legal framework for pharmaceutical research.
Knowles SM
Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
[No Abstract] [Full Text] [Related]
8. Health priorities gain patent reprieve for developing countries.
Cherry M
Nature; 2001 Nov; 414(6862):385. PubMed ID: 11719767
[No Abstract] [Full Text] [Related]
9. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
10. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
11. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2.
Kuhrt K
IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218
[TBL] [Abstract][Full Text] [Related]
12. WTO TRIPS and its effect on the supply and development of medicines in China.
Tanner JA
Hong Kong Med J; 2006 Feb; 12(1):84-6. PubMed ID: 16495599
[No Abstract] [Full Text] [Related]
13. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
14. Intellectual property. Drug patents at the Supreme Court.
Hemphill CS; Sampat B
Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
[No Abstract] [Full Text] [Related]
15. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
Gorlin DI
Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
[No Abstract] [Full Text] [Related]
16. Protect pharmaceutical innovation.
Musselwhite LW; Andrews J
Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
[No Abstract] [Full Text] [Related]
17. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
Burshtein S
Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
[No Abstract] [Full Text] [Related]
18. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
20. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
Trask AV
Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
[No Abstract] [Full Text] [Related]
[Next] [New Search]